Glenn Liu, MD
Developing a Novel Quantitative Total Bone Imaging (QTBI) Methodology to Assess Treatment Response in Metastatic Prostate Cancer The lack of ability to measure tumor response in bone has greatly hindered...Read More
Scott Tomlins
Dr. Tomlins earned a BA in Biology, from Willamette University in Salem, Oregon, a PhD in Molecular and Cellular Pathology from the University of Michigan, Ann Arbor, and is currently...Read More
Yuxi Zhang
The role of prostate cancer stem cell regulated by microRNA in the formation of androgen-independent prostate cancer Male hormones (androgens) fuel prostate cancer progression and the first line of treatment...Read More
David Ulmert
Development of 89Zr-5A10, a novel radiotracer to address AR signaling in advanced prostate cancer The androgen receptor (AR) signaling pathway is a key component in the progression of prostate cancer...Read More
Scott Tagawa
Dr. Tagawa earned a BS in Biology from Georgetown University and an MD degree from USC where he completed a Fellowship in Hematology and Oncology. He is currently an Assistant...Read More
Kit Lam, MD, PhD
Smart Nanoparticles for Imaging and Treatment of Prostate Cancer Dr. Lam is an expert in the area of nanotechnology drug delivery systems. His research group has invented a nanoparticle that...Read More
Christian R. Gomez, PhD
Hypoxia-Regulated DLG7 in Prostate Carcinogenesis and Prognosis An unmet medical need in prostate cancer diagnosis and therapy is the lack of highly-reliable progression biomarkers to monitor efficacy of therapy. Dr....Read More
Peter B. Dervan, PhD
DNA-binding Polyamides as Inhibitors of TMPRSS2-ERG Activity in Prostate Cancer The recent discovery of gene fusions in prostate cancer has established a new biological mechanism for expression of cancer causing...Read More
Nima Sharifi
Dr. Sharifi earned a BS in Biology from Virginia Polytechnic Institute and an MD from the University of Pittsburgh. Following Internal Medicine training at Yale University, Dr. Sharifi completed a...Read More
David Y. Takeda
Targeting TMPRSS2-ERG in Prostate Cancer Approximately half of all prostate cancers carry an abnormal genetic rearrangement that juxtaposes the gene TMPRSS2 against the gene ERG, resulting in the abnormal gene...Read More